WO2003092632A3 - Cyclic peptide anti-cancer agents and methods - Google Patents

Cyclic peptide anti-cancer agents and methods Download PDF

Info

Publication number
WO2003092632A3
WO2003092632A3 PCT/US2003/014373 US0314373W WO03092632A3 WO 2003092632 A3 WO2003092632 A3 WO 2003092632A3 US 0314373 W US0314373 W US 0314373W WO 03092632 A3 WO03092632 A3 WO 03092632A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer agents
methods
cyclic peptide
peptide anti
present
Prior art date
Application number
PCT/US2003/014373
Other languages
French (fr)
Other versions
WO2003092632A2 (en
Inventor
M Reza Ghadiri
Original Assignee
Scripps Research Inst
M Reza Ghadiri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, M Reza Ghadiri filed Critical Scripps Research Inst
Priority to AU2003232077A priority Critical patent/AU2003232077A1/en
Publication of WO2003092632A2 publication Critical patent/WO2003092632A2/en
Publication of WO2003092632A3 publication Critical patent/WO2003092632A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides new types of anti-cancer agents. Methods of using the present anti-cancer agents are also provided.
PCT/US2003/014373 2002-05-06 2003-05-06 Cyclic peptide anti-cancer agents and methods WO2003092632A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003232077A AU2003232077A1 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-cancer agents and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37839502P 2002-05-06 2002-05-06
US60/378,395 2002-05-06

Publications (2)

Publication Number Publication Date
WO2003092632A2 WO2003092632A2 (en) 2003-11-13
WO2003092632A3 true WO2003092632A3 (en) 2007-11-01

Family

ID=29401603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014373 WO2003092632A2 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-cancer agents and methods

Country Status (2)

Country Link
AU (1) AU2003232077A1 (en)
WO (1) WO2003092632A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
WO2010051667A1 (en) * 2008-11-10 2010-05-14 复旦大学 Pharmaceutical compositions comprising cyclic peptide nanotubes and the uses thereof
ES2342874B2 (en) * 2010-02-19 2011-01-27 Fundacio Privada Institut D'investigacio Biomedica De Girona Dr. Josep Trueta INHIBITING CYCLIC PEPTIDES OF CELLULAR GROWTH.
WO2013025099A1 (en) * 2011-08-17 2013-02-21 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Substrates for the detection of periopathogens of the oral cavity
SG11201500111VA (en) 2012-08-29 2015-03-30 Agency Science Tech & Res Peptides and uses thereof
JP2016516752A (en) * 2013-04-02 2016-06-09 ザ スクリプス リサーチ インスティテュート Use of cyclic peptides for the treatment and prevention of atherosclerosis
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
PT3149025T (en) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Cell penetrating peptides and methods of making and using thereof
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
CN106699841B (en) * 2017-01-05 2020-07-24 北京大学深圳研究生院 Self-assembled polypeptide nanorod and preparation method thereof
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3755351A4 (en) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor

Also Published As

Publication number Publication date
AU2003232077A8 (en) 2003-11-17
WO2003092632A2 (en) 2003-11-13
AU2003232077A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU2003247798A1 (en) Nozzles and components thereof and methods for making the same
WO2004058159A3 (en) Branched immunomodulatory compounds and methods of using the same
EP1660638A4 (en) Lipoparticles comprising proteins, methods of making, and using the same
IL212752A0 (en) An molecule directed against the ??-secretase cleavage site of amyloid precursor protein, and uses thereof
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
IL171109A (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2003077867A3 (en) Naltrexone hydrochloride compositions
AU2003212458A1 (en) Cyclo(n)pyrroles and methods thereto
WO2003103571A3 (en) Flavivirus vaccines
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2004009616A3 (en) Ghrelin analogs
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
AU2003295843A8 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2004052312A3 (en) Anti-infectives
WO2003031585A3 (en) Transmembrane serine protease 25
WO2003092631A3 (en) Cyclic peptide anti-viral agents and methods
WO2005087932A3 (en) Vectors for directional cloning
AU2003206367A1 (en) Technical field of the invention
WO2004050613A3 (en) 2-substituted-3-propenamide derivatives and methods of using the same
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
WO2004047751A3 (en) Calcilytic compounds
EP1517879A4 (en) Aminoalkylphenols, methods of using and making the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP